The iCS-digital™ PSC test offers fast and reliable detection of the most common genomic abnormalities in CRISPR/Cas9-edited hPSCs
By combining human pluripotent stem cells (hPSCs) and the CRISPR/Cas9 genome editing technology, new opportunities are created to study disease mechanisms, with enormous therapeutic potential.
Despite the progress in genome engineering, the CRISPR gene editing process consists of major sequential and potentially stressful events, such as clonal expansion, FACS enrichment, drug selection, manual colony picking or stressful single-cell dissociation. By triggering selective pressures on cells, these procedures could favour the generation and selection of genetically abnormal hPSCs, and consequently render these cells unsuitable for further use.
Therefore, efficient and rapid screening of CRISPR-modified hPSCs is essential before their use for research purposes or clinical applications.
